Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Liabilities and Shareholders Equity (2021 - 2025)

Prime Medicine (PRME) has disclosed Liabilities and Shareholders Equity for 5 consecutive years, with $342.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Liabilities and Shareholders Equity rose 15.2% year-over-year to $342.7 million, compared with a TTM value of $1.3 billion through Dec 2025, up 11.12%, and an annual FY2025 reading of $342.7 million, up 15.2% over the prior year.
  • Liabilities and Shareholders Equity was $342.7 million for Q4 2025 at Prime Medicine, down from $385.0 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $385.0 million in Q3 2025 and bottomed at $193.9 million in Q4 2023.
  • Average Liabilities and Shareholders Equity over 5 years is $296.3 million, with a median of $301.9 million recorded in 2021.
  • The sharpest move saw Liabilities and Shareholders Equity tumbled 46.2% in 2023, then surged 53.47% in 2024.
  • Year by year, Liabilities and Shareholders Equity stood at $301.9 million in 2021, then increased by 19.37% to $360.3 million in 2022, then tumbled by 46.2% to $193.9 million in 2023, then skyrocketed by 53.47% to $297.5 million in 2024, then rose by 15.2% to $342.7 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for PRME at $342.7 million in Q4 2025, $385.0 million in Q3 2025, and $279.0 million in Q2 2025.